TY - JOUR
T1 - Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children
T2 - a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
AU - Leukemia Working Group of the Spanish Society of Pediatric Hematology, Oncology (SEHOP)
AU - Fuster, José L
AU - Molinos-Quintana, Agueda
AU - Fuentes, Carolina
AU - Fernández, José M
AU - Velasco, Pablo
AU - Pascual, Toñi
AU - Rives, Susana
AU - Dapena, José L
AU - Sisinni, Luisa
AU - López-Godino, Oriana
AU - Palomo, Pilar
AU - Villa-Alcázar, Marta
AU - Bautista, Francisco
AU - González-Vicent, Marta
AU - López-Duarte, Mónica
AU - García-Morín, Marina
AU - Ramos-Elbal, Eduardo
AU - Ramírez, Manuel
N1 - © 2020 British Society for Haematology and John Wiley & Sons Ltd.
PY - 2020/9
Y1 - 2020/9
N2 - Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a heavily pretreated population with overt relapse was 47·6%. At earlier stages (first/second CR), both antibodies represented a useful tool to reduce minimal residual disease, and/or avoid further toxic chemotherapy until stem cell transplantation. Six patients developed grade 3 reversible non-haematological toxicity. The 12-month overall survival and event-free survival rates were 50·8 ± 26·4% and 38·9 ± 25·3% with blinatumomab, 45·8 ± 26% and 27·5 ± 25% with inotuzumab.
AB - Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a heavily pretreated population with overt relapse was 47·6%. At earlier stages (first/second CR), both antibodies represented a useful tool to reduce minimal residual disease, and/or avoid further toxic chemotherapy until stem cell transplantation. Six patients developed grade 3 reversible non-haematological toxicity. The 12-month overall survival and event-free survival rates were 50·8 ± 26·4% and 38·9 ± 25·3% with blinatumomab, 45·8 ± 26% and 27·5 ± 25% with inotuzumab.
KW - Adolescent
KW - Antibodies, Bispecific/administration & dosage
KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage
KW - Child
KW - Child, Preschool
KW - Disease-Free Survival
KW - Female
KW - Hematology
KW - Humans
KW - Infant
KW - Inotuzumab Ozogamicin/administration & dosage
KW - Male
KW - Medical Oncology
KW - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
KW - Retrospective Studies
KW - Societies, Medical
KW - Spain/epidemiology
KW - Survival Rate
U2 - 10.1111/bjh.16647
DO - 10.1111/bjh.16647
M3 - Article
C2 - 32314348
SN - 0007-1048
VL - 190
SP - 764
EP - 771
JO - British journal of haematology
JF - British journal of haematology
IS - 5
ER -